<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473732</url>
  </required_header>
  <id_info>
    <org_study_id>11-05-196</org_study_id>
    <nct_id>NCT01473732</nct_id>
  </id_info>
  <brief_title>Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity</brief_title>
  <official_title>Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out how well the current drug regimen (including low
      Prograf dose and Myfortic, which is usually recommended to prevent any further deterioration
      in the kidney function) works and how safe it is when compared to a combination of Zortress
      and Myfortic in patients with chronic kidney injury associated with Prograf or Neoral use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: To investigate allograft and peripheral blood cell gene expression patterns
      of patients with CAI by using Affymetrix microarrays.

      Hypothesis 1: Gene expression patterns of patients with biopsy findings suggesting
      calcineurin inhibitor (CNI) toxicity without significant tubulointerstitial infiltrates or
      transplant glomerulopathy might demonstrate upregulation of genes related to tissue injury,
      fibrosis, and extracellular matrix deposition without upregulation of genes related to
      alloimmune response, such as, T and/or B lymphocyte activation markers, surface receptors,
      co-stimulation molecules, adhesion molecules, cytokines, and chemokines comparing to patients
      with significant tubulointerstitial infiltrates and/or transplant glomerulopathy that might
      show upregulation of genes related to alloimmune response, such as, T and/or B lymphocyte
      activation markers, surface receptors, co-stimulation molecules, adhesion molecules,
      cytokines, and chemokines.

      Specific Aim 2: The effect of everolimus (Zortress)/ mycophenolate sodium (EC-MPS, myfortic®)
      treatment on allograft and peripheral gene expression patterns.

      Hypothesis 2: Everolimus (Zortress) and mycophenolate sodium (EC-MPS, myfortic®) treatment
      attenuates the progression of CAI due to CNI toxicity by downregulating the expression of
      genes related to fibrosis, such as, transforming growth factor-β, thrombospondin 1, and
      platelet derived growth factor-C.

      Specific Aim 3: To document the clinical outcomes of everolimus (Zortress) and mycophenolate
      sodium (EC-MPS, myfortic®) in patients with CAI due to CNI toxicity Hypothesis 3: Everolimus
      (Zortress) and mycophenolate sodium (EC-MPS, myfortic®) can attenuate the progression of CAI
      due to CNI toxicity and may improve the creatinine clearance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated after 2 patients due to difficulty in enrollment
  </why_stopped>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in eGFR (Creatinine Clearance) as Measured by Serum Creatinine Blood Test</measure>
    <time_frame>Baseline, One year</time_frame>
    <description>Estimated glomerular filtration rate (eGFR) indicates kidney function. Normal eGFR value for healthy is 80-120ml/min. For transplants, it is expected to be 60-80 ml/min.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Chronic Allograft Injury</condition>
  <condition>Calcineurin Inhibitor Toxicity</condition>
  <arm_group>
    <arm_group_label>Everolimus (Zortress)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced dose Tacrolimus (Prograf)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.</description>
    <arm_group_label>Everolimus (Zortress)</arm_group_label>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Target trough level of Tacrolimus 3-5 ng/ml.</description>
    <arm_group_label>Reduced dose Tacrolimus (Prograf)</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid</intervention_name>
    <description>Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.</description>
    <arm_group_label>Everolimus (Zortress)</arm_group_label>
    <arm_group_label>Reduced dose Tacrolimus (Prograf)</arm_group_label>
    <other_name>Myfortic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients with biopsy proven pure chronic allograft injury due to CNI toxicity.

        Exclusion Criteria:

          1. 24 hour urine protein or spot urine protein/creatinine ratio &gt; 500 mg/day

          2. Estimated glomerular filtration rate (eGFR) &lt; 30 ml/min by modification of Diet in
             Renal Disease( MDRD) or 24 hour urine collection

          3. Patients with Donor-specific antibody (DSA) by Luminex (mean fluorescence intensity
             values &gt; 1,000)

          4. Recipients of multiple organ transplants or ABO-incompatible allograft

          5. Current panel reactive antibody (PRA) greater than 30 percent

          6. Graft loss at randomization

          7. Pregnant women

          8. Previous history of acute rejection

          9. Previous history of allergy or intolerance to Zortress or Myfortic

         10. Platelet count less than 100,000

         11. White Blood Cell (WBC) less than 3,000

         12. Hb less than 9 g/dL or Htc less than 30%

         13. Biopsy findings of

               -  Chronic antibody mediated rejection

               -  Acute rejection

               -  Positive C4d staining

               -  Interstitial infiltrates more than 25% of the area

               -  Transplant glomerulopathy

               -  Recurrent or de novo glomerular disease

               -  Polyoma nephropathy or positive simian virus 40 (SV40) staining
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enver Akalin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center/AECOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>June 11, 2018</results_first_submitted>
  <results_first_submitted_qc>August 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <last_update_submitted>September 17, 2018</last_update_submitted>
  <last_update_submitted_qc>September 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Enver Akalin</investigator_full_name>
    <investigator_title>Prof. Dept of Medicine (Nephrology)</investigator_title>
  </responsible_party>
  <keyword>CNI toxicity</keyword>
  <keyword>CAI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Everolimus (Zortress)+ Mycophenolic Acid(Myfortic)</title>
          <description>Everolimus: Starting dose 1.5 mg bid, target trough level 6-10 ng/ml. Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Both for one year.</description>
        </group>
        <group group_id="P2">
          <title>Reduced Dose Prograf+ Mycophenolic Acid(Myfortic)</title>
          <description>Tacrolimus: Target trough level of Tacrolimus 3-5 ng/ml. Myfortic Min. 360 mg bid and Max. 720 mg bid Both for one year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We did not analyze the data due to no patient enrolled in reduced dose prograf group and 2 patients enrolled in everolimus group did not complete the study due to death and adverse event</population>
      <group_list>
        <group group_id="B1">
          <title>Everolimus (Zortress)+ Mycophenolic Acid(Myfortic)</title>
          <description>Everolimus: Starting dose 1.5 mg bid, target trough level 6-10 ng/ml. Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Both for one year.</description>
        </group>
        <group group_id="B2">
          <title>Reduced Dose Prograf+ Mycophenolic Acid(Myfortic)</title>
          <description>Tacrolimus: Target trough level of Tacrolimus 3-5 ng/ml. Myfortic Min. 360 mg bid and Max. 720 mg bid Both for one year.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="2"/>
                    <measurement group_id="B3" value="63" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in eGFR (Creatinine Clearance) as Measured by Serum Creatinine Blood Test</title>
        <description>Estimated glomerular filtration rate (eGFR) indicates kidney function. Normal eGFR value for healthy is 80-120ml/min. For transplants, it is expected to be 60-80 ml/min.</description>
        <time_frame>Baseline, One year</time_frame>
        <population>The only two patients enrolled did not reach the one year mark; they did not complete the study so there was no data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus (Zortress)+ Mycophenolic Acid(Myfortic)</title>
            <description>Everolimus: Starting dose 1.5 mg bid, target trough level 6-10 ng/ml. Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Both for one year.</description>
          </group>
          <group group_id="O2">
            <title>Reduced Dose Prograf+ Mycophenolic Acid(Myfortic)</title>
            <description>Tacrolimus: Target trough level of Tacrolimus 3-5 ng/ml. Myfortic Min. 360 mg bid and Max. 720 mg bid Both for one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in eGFR (Creatinine Clearance) as Measured by Serum Creatinine Blood Test</title>
          <description>Estimated glomerular filtration rate (eGFR) indicates kidney function. Normal eGFR value for healthy is 80-120ml/min. For transplants, it is expected to be 60-80 ml/min.</description>
          <population>The only two patients enrolled did not reach the one year mark; they did not complete the study so there was no data to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The only two patients enrolled in everolimus group did not complete the study due to events leading to death and one due to proteinuria. The first participant was enrolled in March of 2012 and the study was terminated in August 2012.</time_frame>
      <desc>The two patients enrolled in everolimus group did not complete the study due to events leading to death and one due to proteinuria discontinued everolimus and switched to tacrolimus. The death occurred two months after enrollment. The proteinuria event occurred fours months after enrollment. No patient enrolled in reduced tacrolimus dose group and due to difficulty in enrollment the study is terminated. No data was analyzed for any participant.</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus (Zortress)+ Mycophenolic Acid(Myfortic)</title>
          <description>Everolimus: Starting dose 1.5 mg bid, target trough level 6-10 ng/ml. Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Both for one year.</description>
        </group>
        <group group_id="E2">
          <title>Reduced Dose Prograf+ Mycophenolic Acid(Myfortic)</title>
          <description>Tacrolimus: Target trough level of Tacrolimus 3-5 ng/ml. Myfortic Min. 360 mg bid and Max. 720 mg bid Both for one year.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small bowel obstruction leading to death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Small bowel obstruction lead to sepsis which lead to death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <description>proteinuria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Enver Akalin, Medical Director Kidney Transplant</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-4815</phone>
      <email>eakalin@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

